Niraparib tosylate is a PARP inhibitor used to treat certain types of ovarian, fallopian tube, and primary peritoneal cancers, as well as prostate cancer. It works by inhibiting enzymes needed for DNA repair, leading to cancer cell death, and is used for maintenance therapy in patients who have responded to platinum chemotherapy or to treat advanced prostate cancer in combination with other drugs. It is grouped under the following drug class(es): Antineoplastic agents and PARP Inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include MK-4827-tosylate, 2H-Indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)- and 4-methylbenzenesulfonate (1:1). Its PubChem CID is 78357761.
Niraparib tosylate
| CAS No | 1038915-73-9 |
|---|---|
| Molecular Formula | C26H28N4O4S |
| Molecular Weight | 492.6 g/mol |
| Synonyms | 4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Niraparib tosylate is a PARP inhibitor used to treat certain types of ovarian, fallopian tube, and primary peritoneal cancers, as well as prostate cancer.
The listed CAS number is 1038915-73-9.
The listed molecular formula is C26H28N4O4S.
The listed molecular weight is 492.6 g/mol.
4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide.
The source lists MK-4827-tosylate, 2H-Indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)- and 4-methylbenzenesulfonate (1:1).